Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
OwnerBirgit Bossenmaier, Hans-Joachim Muller +3inventors
InventorsBirgit Bossenmaier, Hans-Joachim Muller, Hans Koll, Mark X. Sliwkowski, Stephen Michael Kelsey
Life of this patent
Estimating the term…
Abstract
Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.
Claims88
A method of identifying a tumor as responsive to treatment with an anti-HER2 antibody comprising:
- a) detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex in a sample of said tumor;
- c) identifying a tumor as responsive to treatment with anti-HER2 antibody when a complex is detected.
A method for identifying tumor cells as responsive to treatment with an antibody inhibiting the association of HER2 with another member of the ErbB receptor family comprising:
- (a) providing a biological sample comprising HER2-positive tumor cells;
- and
- (b) detecting the phosphorylation of an ErbB receptor in said biological sample, wherein said phosphorylation indicates that said tumor cells are responsive to treatment with said antibody.
A method for predicting the response of a subject diagnosed with a HER2-positive tumor to treatment with an antibody inhibiting the association of HER2 with another member of the ErbB receptor family comprising:
- (a) providing a biological sample obtained from said subject, comprising HER2-positive tumor cells;
- and
- (b) detecting phosphorylation of an ErbB receptor in said biological sample,
- wherein said phosphorylation indicates that said patient is likely to respond to treatment with said antibody.
A method for identifying a subject responsive to treatment with an anti-HER2 antibody comprising
- a) detecting phosphorylation of an ErbB receptor in circulating tumor cells of said subject, and
- b) determining that said subject is likely to respond to treatment with an anti-HER2 antibody if said phosphorylation is detected.
A method of treating a patient comprising administering to the patient a therapeutically effective amount of an antibody which binds HER2, wherein the patient is suffering from a tumor which has been determined to comprise HER2/HER3 and/or HER2/HER1 and/or HER2/HER4 heterodimers.
An article of manufacture comprising a container comprising an antibody which binds HER2 and instructions for administering the antibody to a patient suffering from a tumor wherein the tumor has been determined to comprise HER2/HER3 and/or HER2/HER1 and/or HER2/HER4 heterodimers.
A method of treating a patient comprising administering to the patient a therapeutically effective amount of an antibody which binds HER2, wherein the patient is suffering from a tumor which has been determined to have a phosphorylated ErbB receptor.
Dependencies are inferred from the claim text.